Precision BioSciences Announces $75 Million Offering
1. Overview of the Offering
On November 10, 2025, Precision BioSciences, Inc. (Nasdaq: DTIL), a pioneering clinical-stage gene editing company, announced a significant underwritten offering aimed at raising $75 million. This move is centered around the sale of 10,815,000 shares of common stock, coupled with warrants to purchase up to 5,407,500 additional shares. The combined offering price for these shares and warrants is set at $6.14. Additionally, for certain investors opting for alternative arrangements, the company is offering pre-funded warrants that allow for the purchase of up to 1,400,000 shares at a slightly adjusted price of $6.139995.
2. Financial Details
The gross proceeds from this offering, before accounting for underwriting discounts, commissions, and other expenses, are expected to reach approximately $75 million. Each whole warrant carries an exercise price of $7.25 per share, is immediately exercisable, and will remain valid for five years from the issuance date.
The offering will be conducted with participation from both new and existing investors, including notable names such as Aberdeen Investments, Bleichroeder LP, and Driehaus Capital Management, among others. This diverse group of investors underscores the confidence in Precision BioSciences’ innovative approach to gene editing.
3. Use of Proceeds
Precision BioSciences has earmarked the net proceeds from this offering for crucial purposes, including funding ongoing and planned research and development initiatives, as well as for working capital and general corporate purposes. This financial infusion is expected to bolster the company's efforts in advancing its proprietary ARCUS® gene editing platform, which targets high unmet medical needs in genetic and infectious diseases.
4. Expected Closing and Management
The offering is anticipated to close on or around November 12, 2025, pending the satisfaction of customary closing conditions. Guggenheim Securities is serving as the sole book-running manager for this offering, facilitating the transaction process.
5. About Precision BioSciences
Precision BioSciences is dedicated to advancing the field of gene editing through its innovative ARCUS® platform, which distinguishes itself from other technologies by its unique cutting mechanism, smaller size, and straightforward structure. The company’s mission is to deliver lasting cures for a wide array of genetic and infectious diseases, particularly in areas where existing treatment options are inadequate.
6. Conclusion
This strategic move by Precision BioSciences not only highlights the company's commitment to advancing its research but also reflects a robust interest from the investment community in its potential to revolutionize gene editing therapies. As the healthcare landscape continues to evolve, Precision's efforts and innovations may play a pivotal role in addressing some of the most pressing medical challenges of our time.
